Literature DB >> 23695059

Opioids can be useful in the treatment of headache.

Cinzia Finocchi1, Erica Viani.   

Abstract

The use of opioids in headache treatment is very controversial. In the migraine acute attack use of short-acting opioids is not recommended by the principal guidelines but is frequent in North American emergency departments. Their efficacy in migraine acute attack has not been extensively studied but seems to be similar to non-steroidal anti-inflammatory drugs and metoclopramide. Opioids have been never compared to triptans. The principal concerns about the use of opioids regard the possible association with an increased risk of medication-overuse headache and chronic migraine and the risk of abuse and dependence. These risks have to be considered but not overestimated. The association between frequent use and increased risk of chronic migraine has been observed for almost all categories of acute migraine attack drugs. Compared to the reference category of acetaminophen, risk of chronic migraine for opioid use is only moderately higher (with an OR = 1.48). In some cases, when treatment with triptans, non-steroidal anti-inflammatory drugs, or ergotamines is contraindicated or simply ineffective, a judicious prescription of a short-acting opioid for severe migraine attacks can be considered. Chronic migraine is a highly disabling condition. Although the options for prophylaxis therapy of migraine have expanded and improved considerably over recent years, chronic migraine remains very difficult to treat. The results coming from small clinical series are described, suggesting that in expert hands daily long-acting opioids provide an option for the treatment of some individuals with chronic intractable headaches.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23695059     DOI: 10.1007/s10072-013-1416-7

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  41 in total

1.  Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology.

Authors:  S D Silberstein
Journal:  Neurology       Date:  2000-09-26       Impact factor: 9.910

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 3.  Medication-overuse headache and opioid-induced hyperalgesia: A review of mechanisms, a neuroimmune hypothesis and a novel approach to treatment.

Authors:  Jacinta L Johnson; Mark R Hutchinson; Desmond B Williams; Paul Rolan
Journal:  Cephalalgia       Date:  2012-11-09       Impact factor: 6.292

4.  Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.

Authors:  Stephen D Silberstein; Richard B Lipton; David W Dodick; Frederick G Freitag; Nabih Ramadan; Ninan Mathew; Jan L Brandes; Marcelo Bigal; Joel Saper; Steven Ascher; Donna M Jordan; Steven J Greenberg; Joseph Hulihan
Journal:  Headache       Date:  2007-02       Impact factor: 5.887

5.  Single-dose intravenous tramadol for acute migraine pain in adults: a single-blind, prospective, randomized, placebo-controlled clinical trial.

Authors:  Murat Alemdar; Murat Pekdemir; Hamit Macit Selekler
Journal:  Clin Ther       Date:  2007-07       Impact factor: 3.393

Review 6.  Prevalence of headache in Europe: a review for the Eurolight project.

Authors:  Lars Jacob Stovner; Colette Andree
Journal:  J Headache Pain       Date:  2010-05-16       Impact factor: 7.277

7.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

8.  Outpatient treatment of prescription opioid dependence: comparison of two methods.

Authors:  F S Tennant; R A Rawson
Journal:  Arch Intern Med       Date:  1982-10

Review 9.  Use of narcotic analgesics in the emergency department treatment of migraine headache.

Authors:  I Colman; A Rothney; S C Wright; B Zilkalns; B H Rowe
Journal:  Neurology       Date:  2004-05-25       Impact factor: 9.910

10.  Topiramate reduces headache days in chronic migraine: a randomized, double-blind, placebo-controlled study.

Authors:  H-C Diener; G Bussone; J C Van Oene; M Lahaye; S Schwalen; P J Goadsby
Journal:  Cephalalgia       Date:  2007-04-18       Impact factor: 6.292

View more
  3 in total

1.  Spinal endomorphin 2 antinociception and the mechanisms that produce it are both sex- and stage of estrus cycle-dependent in rats.

Authors:  Nai-Jiang Liu; Alan R Gintzler
Journal:  J Pain       Date:  2013-09-29       Impact factor: 5.820

2.  Propofol and alfentanil in treatment of a patient with episodic cluster headache.

Authors:  Sajjad Razavi; Babak Gharaei; Alireza Jafari; Homayoun Aghamohammadi; Alireza Mirkheshti
Journal:  Anesth Pain Med       Date:  2014-05-03

3.  Characterizing opioid use in a US population with migraine: Results from the CaMEO study.

Authors:  Richard B Lipton; Dawn C Buse; Benjamin W Friedman; Lisa Feder; Aubrey Manack Adams; Kristina M Fanning; Michael L Reed; Todd J Schwedt
Journal:  Neurology       Date:  2020-06-11       Impact factor: 9.910

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.